265989-31-9

Usage

Chemical Properties

Brown Solid

InChI:InChI=1/C19H21NO3/c1-14(2)17(21)12-19(22)20-16-10-6-7-11-18(16)23-13-15-8-4-3-5-9-15/h3-11,14H,12-13H2,1-2H3,(H,20,22)

Upstream product

• 20012-63-9 o-(benzyloxy)aniline 
• 4560-41-2 2-benzyloxynitrobenzene 
• 42558-54-3 Methyl 4-methyl-3-oxopentanoate 
• 95-55-6 2-amino-phenol 
• 186663-74-1 tert-butyl (2-hydroxyphenyl)carbamate 
• 186663-07-0 tert-butyl (2-(benzyloxy)phenyl)carbamate 

Downstream Products

• 1020719-18-9 C₂₆H₂₀⁽²⁾H₅NO₃ 
• 887355-33-1 4-methyl-3-oxo-N-(2-benzyloxyphenyl)-2-[1-phenyl-2-(4-fluorophenyl)-2-oxoethyl]pentanamide 
• 265989-41-1 C₄₇H₄₈⁽²⁾H₅FN₂O₆ 
• 265989-42-2 C₄₀H₄₂⁽²⁾H₅FN₂O₆ 
• 777841-55-1 C₃₃H₃₀⁽²⁾H₅FN₂O₆ 
• 265989-50-2 C₃₃H₂₈⁽²⁾H₅FN₂O₅ 
• 265989-39-7 (4R-cis)-1,1-dimethylethyl-6-[2-[2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-[(4-benzyloxyphenyl)carbonyl]-1H-pyrrol-yl]ethyl]-2,2-dimethyl-1,3-dioxane-4-acetate 
• 265989-40-0 ((4R,6R)-6-{2-[2-(4-Fluoro-phenyl)-4-(2-hydroxy-phenylcarbamoyl)-5-isopropyl-3-phenyl-pyrrol-1-yl]-ethyl}-2,2-dimethyl-[1,3]dioxan-4-yl)-acetic acid tert-butyl ester 
• 1346599-89-0 (3R,5R)-7-[2-(4-Fluoro-phenyl)-4-(2-hydroxy-phenylcarbamoyl)-5-isopropyl-3-phenyl-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid tert-butyl ester 
• 214217-86-4 o-Hydroxyatorvastatin 
• 1020719-43-0 C₃₃H₂₅⁽²⁾H₅FNO₄ 
• 163217-74-1 o-Hydroxyatorvastatin lactone 
• 163217-77-4 4-Methyl-3-oxo-2-[1-phenyl-meth-(Z)-ylidene]-pentanoic acid (2-benzyloxy-phenyl)-amide 

Relevant academic research and scientific papers

IMPROVED PROCESS FOR THE PREPARATION OF [3R,5R]-2-FLUOROPHENYL-β,δ- DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(2-HYDROXYPHENYLAMINO)- CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID, SODIUM SALT

The present invention relates to an improved process for the preparation of [3R,5R]-2-fluorophenyl-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(2-hydroxyphenylamino)-carbonyl]-1H-pyrrole-1-heptanoic acid sodium salt compound of formula- 1 represented by the following structural formula:

SUBSTITUTED PYRROLE DERIVATIVES AS HMG-COA REDUCTASE INHIBITORS

The present invention relates to substituted pyrrole derivatives of Formula (I), wherein (Y), with the proviso that one of R2, R4 and R5 is a heterocycle and with the further provision that if R2 is not a heterocycle then either R4 or R5 alone is not unsubstituted pyridyl, which can be used as 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors. Compounds disclosed herein can function as cholesterol lowering agents and can be used for the treatment of cholesterol-related diseases and related symptoms. Processes for the preparation of disclosed compounds are provided, as well as pharmaceutical compositions containing the disclosed compounds, and methods of treating cholesterol-related diseases and related symptoms.

Synthesis of deuterium-labeled atorvastatin and its metabolites for use as internal standards in a LC/MS/MS method developed for quantitation of the drug and its metabolites in human serum

D5-labeled isotopomers of atorvastatin, atorvastatin lactone and its hydroxy metabolites were synthesized as internal standards for use in a LC/MS/MS method developed for the simultaneous quantitative determination of atorvastatin and its hydroxy metabolites in human serum. d5-Atorvastatin and d5-atorvastatin lactone were prepared from d5-aniline whereas their corresponding hydroxy metabolites were synthesized using d5-benzaldehyde.